## CORRECTION

**Open Access**

# Correction: Early sevoflurane sedation in severe COVID19-related lung injury patients. A pilot randomized controlled trial

Beatrice Beck-Schimmer[1,2], Erik Schadde[2,3], Urs Pietsch[4], Miodrag Filipovic[4], Seraina Dübendorfer-Dalbert[5], Patricia Fodor[5], Tobias Hübner[6], Reto Schuepbach[7], Peter Steiger[7], Sascha David[7], Bernard D. Krüger[1], Thomas A. Neff[6] and Martin Schläpfer[1,2*]

**Correction: Annals of Intensive Care (2024) 14:41**
https://doi.org/10.1186/s13613-024-01276-4

In Table 2 of this article [1], the data in the [Primary endpoint reached, n (%)] headed **Sevoflurane**, should be listed as 11 (39) not 11 (16).

Primary Endpoint Reached, it reads, that 11 patients in the sevoflurane and 13 in the propofol group reached the primary endpoint. This is correct, but the percentages are incorrect, they should be 39 and 41%, respectively.

Table 2 Primary and secondary outcomes (uncorrected)

| Variable | Sevoflurane | Control | p-value |
|---|---|---|---|
| *Primary outcome* | *n=28* | *n=32* | |
| Primary endpoint reached, n (%) | 11 (16) | 13 (41) | 0.916 |

*Correspondence:
Martin Schläpfer
martin.schlaepfer@uzh.ch
[1] Institute of Anesthesiology, University Hospital Zurich University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
[2] Institute of Physiology, University of Zurich, Zurich, Switzerland
[3] Department of Surgery, Rush University, Chicago, IL, USA
[4] Division of Anesthesiology, Intensive Care, Rescue and Pain Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
[5] Institute of Anesthesia and Intensive Care Medicine, City Hospital Triemli, Zurich, Switzerland
[6] Department of Anesthesia and Intensive Care Medicine, Cantonal Hospital Muensterlingen, Muensterlingen, Switzerland
[7] Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland

| Variable | Sevoflurane | Control | p-value |
|---|---|---|---|
| Death, n (%) | 5 (16) | 5 (18) | 0.817 |
| *Survivors* | *n=23* | *n=27* | |

2: Primary and secondary outcomes (corrected)

| Variable | Sevoflurane | Control | p-value |
|---|---|---|---|
| *Primary outcome* | *n=28* | *n=32* | |
| Primary endpoint reached, n (%) | 11 (39) | 13 (41) | 0.916 |
| Death, n (%) | 5 (16) | 5 (18) | 0.817 |
| *Survivors* | *n=23* | *n=27* | |

The original article has been corrected.

Published online: 16 June 2024

**Reference**
1. Beck-Schimmer B, Schadde E, Pietsch U, Filipovic M, Dübendorfer-Dalbert S, Fodor P, Hübner T, Schuepbach R, Steiger P, David S, Krüger BD, Neff TA, Schläpfer M. Early sevoflurane sedation in severe COVID19-related lung injury patients. A pilot randomized controlled trial. Ann Intensive Care. 2024;14:41. https://doi.org/10.1186/s13613-024-01276-4.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.